Evoke Pharma (NASDAQ:EVOK) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Friday.

A number of other equities research analysts have also recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Evoke Pharma in a report on Monday, September 18th. FBR & Co restated a “buy” rating and issued a $10.00 price objective on shares of Evoke Pharma in a report on Monday, October 30th. Zacks Investment Research upgraded shares of Evoke Pharma from a “strong sell” rating to a “hold” rating in a report on Thursday, October 12th. Northland Securities restated a “buy” rating and issued a $10.00 price objective on shares of Evoke Pharma in a report on Wednesday, October 18th. Finally, Seaport Global Securities restated a “buy” rating and issued a $10.00 price objective on shares of Evoke Pharma in a report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $9.00.

Shares of Evoke Pharma (NASDAQ:EVOK) opened at $2.67 on Friday. Evoke Pharma has a fifty-two week low of $1.42 and a fifty-two week high of $4.55.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.13). During the same period last year, the firm posted ($0.29) EPS. equities analysts anticipate that Evoke Pharma will post -0.75 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of EVOK. State Treasurer State of Michigan lifted its stake in shares of Evoke Pharma by 37.0% in the second quarter. State Treasurer State of Michigan now owns 400,000 shares of the specialty pharmaceutical company’s stock worth $1,024,000 after buying an additional 108,034 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Evoke Pharma by 15.1% in the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after buying an additional 68,544 shares in the last quarter. Finally, Sphera Funds Management LTD. lifted its stake in shares of Evoke Pharma by 14.2% in the third quarter. Sphera Funds Management LTD. now owns 571,022 shares of the specialty pharmaceutical company’s stock worth $1,907,000 after buying an additional 71,022 shares in the last quarter. Hedge funds and other institutional investors own 13.64% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “ValuEngine Lowers Evoke Pharma (EVOK) to Strong Sell” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/12/02/valuengine-lowers-evoke-pharma-evok-to-strong-sell.html.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Receive News & Stock Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related stocks with our FREE daily email newsletter.